H1N1 Vaccine Update: Big Sales To Come In Fourth Quarter, Mfrs. Say
Executive Summary
The pandemic influenza situation is leaving the biopharmaceutical industry in a healthy state - with early reports of vaccine sales having notable impact on manufacturers' bottom lines, revitalization for waning antiviral products and accelerated pathways for novel products
You may also be interested in...
Possibility Of A Pandemic Helped GSK’s Q-Pan H5N1 Flu Vaccine Get Panel Support
FDA’s Vaccines and Related Biological Products Advisory Committee said in twin 14-0 votes that immunogenicity and safety data are sufficient to support approval.
FDA Scientists Take Recombinant Step Toward Faster Development Of Flu Vaccines
Scientists at FDA have taken a step toward speeding the approval of influenza vaccines: They have demonstrated a faster way to produce the reagent used to evaluate a vaccine's potency.
FDA Scientists Take Recombinant Step Toward Faster Development Of Flu Vaccines
Scientists at FDA have taken a step toward speeding the approval of influenza vaccines: They have demonstrated a faster way to produce the reagent used to evaluate a vaccine's potency.